Hematopoietic Stem Cell Transplantation Positively Affects the Natural History of Cancer in Nijmegen Breakage Syndrome
- 15 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (2), 575-584
- https://doi.org/10.1158/1078-0432.ccr-20-2574
Abstract
Purpose: Nijmegen breakage syndrome (NBS) is a DNA repair disorder with a high predisposition to hematologic malignancies. Experimental Design: We describe the natural history of NBS, including cancer incidence, risk of death, and the potential effectiveness of hematopoietic stem cell transplantation (HSCT) in preventing both pathologies: malignancy and immunodeficiency. Results: Among 241 patients with NBS enrolled in the study from 11 countries, 151 (63.0%) patients were diagnosed with cancer. Incidence rates for primary and secondary cancer, tumor characteristics, and risk factors affecting overall survival (OS) were estimated. The cumulative cancer incidence was 40.21% ± 3.5% and 77.78% ± 3.4% at 10 years and 20 years of follow-up, respectively. Most of the tumors n = 95 (62.9%) were non-Hodgkin lymphomas. Overall, 20 (13.2%) secondary malignancies occurred at a median age of 18 (interquartile range, 13.7–21.5) years. The probability of 20-year overall survival (OS) for the whole cohort was 44.6% ± 4.5%. Patients who developed cancer had a shorter 20-year OS than those without malignancy (29.6% vs. 86.2%; P < 10−5). A total of 49 patients with NBS underwent HSCT, including 14 patients transplanted before malignancy. Patients with NBS with diagnosed cancer who received HSCT had higher 20-year OS than those who did not (42.7% vs. 30.3%; P = 0.038, respectively). In the group of patients who underwent preemptive transplantation, only 1 patient developed cancer, which is 6.7 times lower as compared with nontransplanted patients [incidence rate ratio 0.149 (95% confidence interval, 0.138–0.162); P < 0.0001]. Conclusions: There is a beneficial effect of HSCT on the long-term survival of patients with NBS transplanted in their first complete remission of cancer.Keywords
Other Versions
Funding Information
- Horizon 2020 (N643578)
- National Centre for Research and Development (ERANET-E-Rare-3/I/EuroCID/04/2016)
- National Science Centre (2017/26/D/NZ5/00811)
- LEukemia GENe Discovery (COST Action - CA16223)
This publication has 26 references indexed in Scilit:
- The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and AdultsAsco Educational Book, 2014
- Telomere dysfunction and its role in haematological cancerBritish Journal of Haematology, 2012
- Nijmegen breakage syndrome (NBS)Orphanet Journal of Rare Diseases, 2012
- DNA repair: the link between primary immunodeficiency and cancerAnnals of the New York Academy of Sciences, 2011
- Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective surveyBritish Journal of Haematology, 2011
- Successful SCT for Nijmegen breakage syndromeBone Marrow Transplantation, 2009
- Non‐Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS)Pediatric Blood & Cancer, 2008
- Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formationThe Journal of Pathology, 2008
- Cancer risk according to type and location of ATM mutation in ataxia‐telangiectasia familiesGenes, Chromosomes and Cancer, 2004
- Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populationsEuropean Journal of Human Genetics, 2000